OmniAb, Inc. (OABI) Stock Analysis

OmniAb’s principal competitive advantage lies in its proprietary transgenic animal platforms—OmniRat, OmniMouse, OmniChicken, and OmniUltra—which enable partners to generate fully human antibodies with high diversity and developability. This technology is protected by a robust patent portfolio and trade secrets, making replication by competitors difficult. The company’s “Biological Intelligence” approach, which leverages in vivo immune systems, is widely regarded as the gold standard for antibody discovery, offering higher clinical success rates than in vitro or computational methods.

Switching costs are exceptionally high: once a partner initiates a drug discovery program using OmniAb’s platform, changing providers would require restarting years of work, effectively locking in long-term royalty streams. As of June 2026, OmniAb has 110 active partners and 425 active programs—substantially more than direct rival AbCellera (178 programs), and a broader reach than Alloy Therapeutics or Adimab. Seven approved drugs and 34 clinical-stage programs validate the platform’s effectiveness.

OmniAb’s business model—upfront fees, milestones, and royalties—diversifies risk across a large portfolio, reducing dependence on any single program. The company’s culture emphasizes scientific rigor and partner alignment, supporting high customer retention and repeat business. However, compared to cash-rich competitors like AbCellera, OmniAb’s financial resources are more limited, which could constrain R&D investment if industry funding tightens. Nonetheless, its scale, technological differentiation, and embedded customer relationships create a durable moat.